Normal.dot

1 Name of Determination

(1) This instrument is the National Health (April 2023 Price Reductions) (Exercise of Ministerial discretion) Determination (No.1) 2023.

(2) This instrument may also be cited as PB 19 of 2023.

2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. The whole of this instrument	The day this instrument is registered.

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Definition

Note: A number of expressions used in this instrument are defined in Part VII the Act.

In this instrument:

Act means the National Health Act 1953.

catch-up price reduction day has the same meaning as in subsection 99ACN(6) of the Act.

4 Authority

This instrument is made under subsection 99ACC(5C) and subsection 99ACF(3) of the Act.

5 Brand of pharmaceutical item (combination item) not subject to a price reduction

I determine, under paragraph 99ACC(5C)(a) of the Act, that the approved ex-manufacturer price, and each of the claimed prices (if applicable) of each single brand of combination item specified in column 2 as an item in the table in Schedule 1 is not reduced under subsection 99ACC(2) or subsection 99ACC(5) of the Act, as appropriate, in relation to the reduction day.

6 Brand of pharmaceutical item not subject to a price reduction

I determine, under paragraph 99ACF(3)(a) of the Act, that the approved ex-manufacturer price, and each of the claimed prices (if applicable) of each brand of pharmaceutical item specified in column 2 as an item in the table in Schedule 2 is not reduced under a provision mentioned in item 8 of the table in subsection 99ACF(1) of the Act, as appropriate, in relation to the catch-up price reduction day.

7 Brand of pharmaceutical item subject to a lower price reduction than would otherwise apply

I determine, under paragraph 99ACF(3)(b) of the Act, that the approved ex-manufacturer price, and each of the claimed prices (if applicable) of a brand of pharmaceutical item specified in column 2 of an item in the table in Schedule 3 is reduced under a provision mentioned in item 8 of the table in subsection 99ACF(1) of the Act, as appropriate, in relation to the catch-up price reduction day by the percentage specified in column 3 of the table item.

Schedule 1—Brands of pharmaceutical items (combination items) with approved ex-manufacturer price not reduced

Column 1	Column 2
Item	Brand of Pharmaceutical Item
	Drug	Form	Manner of administration	Brand(s)
1	Nirmatrelvir and ritonavir	Pack containing 4 tablets nirmatrelvir 150 mg and 2 tablets ritonavir 100 mg, 5	Oral	Paxlovid

Schedule 2— Brands of pharmaceutical items with approved ex-manufacturer price not reduced

Column 1	Column 2
Item	Brand of Pharmaceutical Item
	Drug	Form	Manner of administration	Brand(s)
1	Buprenorphine with naloxone	Film (soluble) 2 mg (as hydrochloride)-0.5 mg (as hydrochloride)	Sublingual	Suboxone Film 2/0.5
2	Chorionic gonadotrophin	Injection set containing powder for injection 1,500 units, 3 and solvent 1 mL, 3 (s19A)	Injection	Brevactid 1500 I.E
3	Chorionic gonadotrophin	Powder for injection 5,000 units with solvent (s19A)	Injection	Choriomon 5000 I.E
4	Colestyramine	Sachets containing 4.7 g oral powder (equivalent to 4 g colestyramine), 50	Oral	Questran Lite
5	Erythromycin	Powder for oral liquid 200 mg (as ethyl succinate) per 5 mL, 100 mL	Oral	E-Mycin 200
6	Erythromycin	Powder for oral liquid 400 mg (as ethyl succinate) per 5 mL, 100 mL	Oral	E-Mycin 400
7	Estradiol	Tablet 2 mg	Oral	Zumenon
8	Estradiol and estradiol with dydrogesterone	Pack containing 14 tablets estradiol 1 mg and 14 tablets estradiol 1 mg with dydrogesterone 10 mg	Oral	Femoston 1/10
9	Estradiol and estradiol with dydrogesterone	Pack containing 14 tablets estradiol 2 mg and 14 tablets estradiol 2 mg with dydrogesterone 10 mg	Oral	Femoston 2/10
10	Hydralazine	Tablet containing hydralazine hydrochloride 50 mg	Oral	Alphapress 50
11	Hydromorphone	Oral solution containing hydromorphone hydrochloride 1 mg per mL, 1 mL	Oral	Hydromorphone hydrochloride oral solution, USP (Medsurge)
12	Imipramine	Tablet containing imipramine hydrochloride 25 mg (s19A)	Oral	Imipramine (Leading)
13	Mianserin	Tablet containing mianserin hydrochloride 10 mg	Oral	Lumin 10
14	Mianserin	Tablet containing mianserin hydrochloride 20 mg	Oral	Lumin 20
15	Pancreatic extract	Capsule (containing enteric coated minimicrospheres) providing not less than 10,000 BP units of lipase activity	Oral	Creon 10,000
16	Pancreatic extract	Capsule (containing enteric coated minimicrospheres) providing not less than 25,000 BP units of lipase activity	Oral	Creon 25,000
17	Pancreatic extract	Capsule (containing enteric coated minimicrospheres) providing not less than 35,000 BP units of lipase activity	Oral	Creon 35,000
18	Pancreatic extract	Granules (enteric coated) providing not less than 5,000 BP units of lipase activity per 100 mg, 20 g	Oral	Creon Micro
19	Penicillamine	Tablet 125 mg	Oral	D-Penamine
20	Penicillamine	Tablet 250 mg	Oral	D-Penamine
21	Phenelzine	Tablet 15 mg (as sulfate) s19A	Oral	Nardil (Canada)
22	Pyridostigmine	Tablet containing pyridostigmine bromide 180 mg (modified release) s19A	Oral	Pyridostigmine Bromide Extended-Release Tablets (Rising)
23	Tenecteplase	Powder for injection 50 mg with solvent (s19A)	Injection	TNKase (Canada) Medsurge Healthcare Pty Ltd
24	Warfarin	Tablet containing warfarin sodium 1 mg	Oral	Coumadin
25	Warfarin	Tablet containing warfarin sodium 1 mg	Oral	Marevan
26	Warfarin	Tablet containing warfarin sodium 2 mg	Oral	Coumadin
27	Warfarin	Tablet containing warfarin sodium 3 mg	Oral	Marevan
28	Warfarin	Tablet containing warfarin sodium 5 mg	Oral	Coumadin
29	Warfarin	Tablet containing warfarin sodium 5 mg	Oral	Marevan

Schedule 3 — Brands of pharmaceutical items with approved ex-manufacturer price reduced by a lower percentage than would otherwise apply

Column 1	Column 2				Column 3
Item	Brand of pharmaceutical item				% reduction
	Drug	Form	Manner of administration	Brand
1	Aripiprazole	Powder for injection 300 mg (as monohydrate) with diluent	Injection	Abilify Maintena	4.84%
2	Aripiprazole	Powder for injection 400 mg (as monohydrate) with diluent	Injection	Abilify Maintena	4.84%
3	Cladribine	Tablet 10 mg	Oral	Mavenclad	5%
4	Methylprednisolone	Cream containing methylprednisolone aceponate 1 mg per g, 15 g	Application	Advantan	19%
5	Methylprednisolone	Fatty ointment containing methylprednisolone aceponate 1 mg per g, 15 g	Application	Advantan (Fatty)	19%
6	Methylprednisolone	Lotion containing methylprednisolone aceponate 1 mg per g, 20 g	Application	Advantan	16.67%
7	Methylprednisolone	Ointment containing methylprednisolone aceponate 1 mg per g, 15 g	Application	Advantan	19%